Raymond James Keeps Their Buy Rating on Spark Therapeutics (ONCE)


In a report released today, Reni Benjamin from Raymond James maintained a Buy rating on Spark Therapeutics (NASDAQ: ONCE), with a price target of $82. The company’s shares closed yesterday at $56.01.

Benjamin wrote:

“We are maintaining our Outperform rating for Spark. Yesterday morning the company reported 2Q18 financial results and provided an update on its gene therapy programs. While the market reaction was decidedly negative (-28%), we continue to believe that SPK 8011 has demonstrated solid efficacy, in terms of annualized bleeding rate (ABR) and annualized infusion rate (AIR), as well as a safety profile, which will likely get better with prophylactic steroid treatment.”

According to TipRanks.com, Benjamin is a 3-star analyst with an average return of 3.4% and a 40.1% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Bellicum Pharmaceuticals, Adaptimmune Therapeutics, and Voyager Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Spark Therapeutics with a $72.77 average price target, a 29.9% upside from current levels. In a report released yesterday, William Blair also maintained a Buy rating on the stock.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $96.59 and a one-year low of $41.06. Currently, Spark Therapeutics has an average volume of 666.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases.

Read More on ONCE:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts